Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations Research Letter

  

Authors:	Kunvarjee, B.; Bidgoli, A.; Madan, R. P.; Vidal, E.; McAvoy, D.; Hosszu, K. K.; Scaradavou, A.; Spitzer, B. G.; Curran, K. J.; Cancio, M.; Harris, A. C.; O'Reilly, R. J.; Kung, A. L.; Prockop, S.; Boelens, J. J.; Oved, J. H.
Title:	Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations
Keywords:	child; clinical article; event free survival; preschool child; overall survival; genetics; busulfan; fludarabine; case report; area under the curve; letter; metabolism; stat1 protein; cyclophosphamide; hematopoietic stem cell transplantation; monoclonal antibody; chimera; antibodies, monoclonal; myeloablative conditioning; cd4+ t lymphocyte; graft versus host reaction; cd4 antigen; cytokine release; immunosuppressive treatment; tacrolimus; bone marrow transplantation; thymocyte antibody; platelet count; antiviral therapy; neutralizing antibody; antibodies, neutralizing; reconstructive surgery; failure to thrive; stat1 transcription factor; mycophenolate mofetil; gain of function mutation; fungemia; humans; human; female; stat1 protein, human; mucocutaneous candidiasis; candidiasis, chronic mucocutaneous; emapalumab; mycobacterium abscessus infection
Journal Title:	Journal of Allergy and Clinical Immunology
Volume:	152
Issue:	3
ISSN:	0091-6749
Publisher:	Mosby Elsevier
Date Published:	2023-09-01
Start Page:	815
End Page:	817
Language:	English
DOI:	10.1016/j.jaci.2023.05.016
PUBMED:	37367708
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85169830233&doi=10.1016%2fj.jaci.2023.05.016&partnerID=40&md5=e8d2d094288b3a1bb37c5725cbc440fe
Notes:	Letter -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Joseph Oved -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/209896